Internal Medicine, Hematology & Oncology · Bryn Mawr, PA
NPI
1013171420
Since 2008
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
825 Old Lancaster Rd, Suite 320
Bryn Mawr, PA, 19010
Phone (610) 527-3800
Groups this clinician bills Medicare through
Medicare paid, 2024
$9.2M
544,836 services
Medicare patients, 2024
813
Average age 75
Drug cost, 2024
$9.7M
3,113 prescriptions
Company payments, 2025
$45K
From 37 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Sameer Gupta was code J0881 (injection, darbepoetin alfa, 1 microgram (non-esrd use)), 81,400 times for 65 patients. In total Sameer Gupta billed 544,836 services in 116 codes, and Medicare paid $9.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-04-05.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 81,400 | 65 | $2.33 | $189K |
| Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | Office | 64,800 | 17 | $0.22 | $14K |
| J9299 Injection, nivolumab, 1 mg | Office | 53,763 | 17 | $24.54 | $1.3M |
| J1453 Injection, fosaprepitant, 1 mg | Office | 45,150 | 50 | $0.13 | $6,021 |
| J9271 Injection, pembrolizumab, 1 mg | Office | 38,800 | 27 | $44.68 | $1.7M |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 19,815 | 11 | $39.10 | $775K |
| J0897 Injection, denosumab, 1 mg | Office | 11,400 | 82 | $20.10 | $229K |
| J9267 Injection, paclitaxel, 1 mg | Office | 11,260 | 14 | $0.08 | $905 |
| J1456 Injection, fosaprepitant (teva), not therapeutically equivalent to j1453, 1 mg | Office | 9,450 | 23 | $1.92 | $18K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 7,410 | 53 | $15.68 | $116K |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 7,050 | 19 | $36.69 | $259K |
| J1626 Injection, granisetron hydrochloride, 100 mcg | Office | 7,007 | 68 | $0.30 | $2,085 |
| J2919 Injection, methylprednisolone sodium succinate, 5 mg | Office | 4,964 | 96 | $0.25 | $1,221 |
| 96375 Injection Administration | Office | 4,444 | 179 | $12.38 | $55K |
| J9041 Injection, bortezomib, 0.1 mg | Office | 4,353 | 12 | $1.42 | $6,203 |
By year: 2022 $6.3M for 501,040 services; 2023 $7.7M for 559,530 services; 2024 $9.2M for 544,836 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 1,419 | 212 | $4.89 | $6,934 |
Medicare prescription drug claims, 2024
In 2024, the drug Sameer Gupta prescribed most often to Medicare patients was Anastrozole, with 290 prescriptions and refills. In total Sameer Gupta wrote 3,113 Medicare prescriptions that cost $9.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 290 | 674 | 77 | $5,003 |
| Eliquis Apixaban | 216 | 300 | 41 | $168K |
| Acyclovir Generic | 156 | 272 | 34 | $2,603 |
| Xarelto Rivaroxaban | 142 | 272 | 31 | $147K |
| Prednisone Generic | 136 | 147 | 37 | $500 |
| Letrozole Generic | 119 | 304 | 33 | $2,967 |
| Verzenio Abemaciclib | 102 | 102 | Under 11 | $1.1M |
| Ondansetron Hcl Generic | 98 | 102 | 70 | $1,065 |
| Valacyclovir Valacyclovir Hcl | 85 | 135 | 22 | $2,438 |
| Prochlorperazine Maleate Generic | 73 | 73 | 55 | $1,199 |
| Lenalidomide Generic | 69 | 69 | Under 11 | $975K |
| Hydroxyurea Generic | 65 | 135 | 17 | $1,421 |
| Gabapentin Generic | 59 | 81 | 15 | $870 |
| Revlimid Lenalidomide | 55 | 55 | Under 11 | $1.3M |
| Dexamethasone Generic | 53 | 55 | 19 | $753 |
Brand drugs: 895 claims; generic drugs: 2,218 claims; opioid claims: 48.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Sameer Gupta $45K ($45K in general payments such as food, travel and fees) from 37 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $35K.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 28 | $35K |
| Daiichi Sankyo Inc. 4568.T | 17 | $7,378 |
| Novartis Pharmaceuticals Corporation NVS | 17 | $389 |
| Pfizer Inc. PFE | 19 | $315 |
| Abbvie Inc. ABBV | 10 | $204 |
| Incyte Corporation INCY | 5 | $124 |
| Shield Therapeutics Inc STX.L | 2 | $107 |
| Puma Biotechnology, Inc. PBYI | 4 | $90.49 |
| Exelixis Inc. EXEL | 5 | $89.21 |
| GlaxoSmithKline, LLC. GSK | 3 | $79.86 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.